Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
UNCY Stock Chart & Stats
$6.20
-$0.03(-4.01%)
At close: 4:00 PM EST
$6.20
-$0.03(-4.01%)
Day’s Range― - ―
52-Week Range$3.71 - $11.00
Previous CloseN/A
Volume1.16M
Average Volume (3M)615.47K
Market Cap
$133.25M
Enterprise Value$90.82M
Total Cash (Recent Filing)$42.70M
Total Debt (Recent Filing)$265.00K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 26, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding21,491,396
10 Day Avg. Volume540,055
30 Day Avg. Volume615,465
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)7.16
Price to Sales (P/S)0.00
P/FCF Ratio-1.86
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-332.66
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$39.50Price Target Upside537.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger EquityVery low leverage and meaningful equity improvement provide lasting financial flexibility to fund clinical development and remediate regulatory issues. A stronger balance sheet reduces short-term solvency risk and supports continued R&D investment without immediate refinancing pressure.
Sufficient Near-Term Cash RunwayA runway into 2027 materially reduces near-term liquidity risk, allowing the company to pursue FDA resubmission and potential launch activities without urgent capital raises. This stability supports execution on regulatory milestones and gives management time to de‑risk OLC development.
Product Differentiation (OLC Reduces Pill Burden)A therapy that reduces pill burden addresses a durable clinical pain point in dialysis care and can create a sustainable commercial advantage if approved. Improved adherence can translate to stronger formulary positioning and longer-term market share versus existing phosphate binders.
Bears Say
Pre-Revenue With Sustained Cash BurnPersistent zero revenue and large negative operating and free cash flow create ongoing financing needs. Over the medium term, continued cash burn can dilute shareholders, constrain R&D choices, and force strategic tradeoffs if clinical or regulatory setbacks delay commercialization.
Manufacturing Compliance Issue Caused CRLA third‑party manufacturing compliance problem that triggered a CRL is a structural execution risk: remediation can be time-consuming, costly, and may require supply‑chain changes. Such issues can materially delay approval and compress the commercial window upon launch.
Revenue Dependent On Regulatory Approval Of OLCThe business model is highly binary: long‑term revenue hinges on one lead candidate achieving regulatory approval and market adoption. This single‑asset dependence increases commercial and regulatory risk, leaving the company vulnerable if OLC fails or faces market access challenges.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $3.71 and its highest was $11.00 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $133.25M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 36 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $0.2.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -0.42.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 21,491,396 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went up 7.307%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (537.10% Upside)
$39.50 (537.10% Upside)
Blogger Sentiment
Bullish
UNCY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.71%
12-Months-Change
Fundamentals
Return on Equity
-102.47%
Trailing 12-Months
Asset Growth
31.20%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$39.50
▲(537.10% Upside)
Technical Analysis
Ownership Overview
21.10%
Insiders
3.16% Mutual Funds
0.11% Other Institutional Investors
72.51% Public Companies and
Individual Investors